Triple
T17871512
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Givlaari |
E446846
|
entity |
| Predicate | hasMolecularTarget |
P37016
|
FINISHED |
| Object | aminolevulinate synthase 1 |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: aminolevulinate synthase 1 | Statement: [Givlaari, hasMolecularTarget, aminolevulinate synthase 1]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: aminolevulinate synthase 1 Context triple: [Givlaari, hasMolecularTarget, aminolevulinate synthase 1]
-
A.
indoleamine 2,3-dioxygenase 1
Indoleamine 2,3-dioxygenase 1 is an immune-regulatory enzyme that catalyzes the initial oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation, tolerance, and tumor immune evasion.
-
B.
UGT1A1
UGT1A1 is a liver enzyme that glucuronidates bilirubin and various drugs, playing a key role in their detoxification and elimination from the body.
-
C.
indoleamine 2,3-dioxygenase 2
Indoleamine 2,3-dioxygenase 2 is an immune-regulatory heme-containing enzyme that catalyzes the oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation and immune tolerance.
-
D.
CYP1A2
CYP1A2 is a liver enzyme of the cytochrome P450 family that plays a key role in the metabolism of various drugs and xenobiotics.
-
E.
Luzein
Luzein is a Swiss municipality in the canton of Graubünden, known for its alpine landscape and traditional rural character.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: aminolevulinate synthase 1 Target entity description: Aminolevulinate synthase 1 is a mitochondrial enzyme that catalyzes the first and rate-limiting step of heme biosynthesis in non-erythroid cells.
-
A.
indoleamine 2,3-dioxygenase 1
Indoleamine 2,3-dioxygenase 1 is an immune-regulatory enzyme that catalyzes the initial oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation, tolerance, and tumor immune evasion.
-
B.
UGT1A1
UGT1A1 is a liver enzyme that glucuronidates bilirubin and various drugs, playing a key role in their detoxification and elimination from the body.
-
C.
indoleamine 2,3-dioxygenase 2
Indoleamine 2,3-dioxygenase 2 is an immune-regulatory heme-containing enzyme that catalyzes the oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation and immune tolerance.
-
D.
CYP1A2
CYP1A2 is a liver enzyme of the cytochrome P450 family that plays a key role in the metabolism of various drugs and xenobiotics.
-
E.
Luzein
Luzein is a Swiss municipality in the canton of Graubünden, known for its alpine landscape and traditional rural character.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8b9f4c22c819093c2680434472894 |
completed | April 10, 2026, 8:51 a.m. |
| NER | Named-entity recognition | batch_69e49aa30ff8819090c51c1d7767e952 |
completed | April 19, 2026, 9:04 a.m. |
Created at: April 10, 2026, 10:18 a.m.